Company intelligence / Profile preview
Oncoinvent AS
Oslo, Norwayoncoinvent.com ↗
- Ownership
- Public · ONCIN
- Development stage
- Phase 2
01
Overview
Oncoinvent’s lead product candidate Radspherin® has completed Phase 1 safety and biodistribution studies with good patient recruitment. The company has amended both ongoing Phase 1 trials into Phase 2a to gather additional data. Early results show significant reduction in tumor cell growth and promising long-term survival rates for patients with peritoneal carcinomatosis of colorectal origin
- Therapeutic areas
- Oncology
- Modalities
- Radiopharmaceuticals (specifically alpha-emitting radioactive microspheres)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Financials
- Market cap
- $29.7M
- Total revenue
- $2.5M
- Enterprise value
- $18.6M
Beyond the preview
Go deeper on Oncoinvent AS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oncoinvent AS.